Navigation Links
Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting

IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies, today announced that four scientific posters featuring both patient cases and laboratory research in which the Thermogard XP(TM) was utilized will be presented this week at the American Society of Anesthesiologists (ASA) Annual Meeting, taking place in Orlando.

Dr. Arie Blitz, Director of Heart Transplantation and Assist Device Surgery at University Hospitals of Cleveland Case Medical Center, and President of the Cleveland chapter of the American Heart Association, will present the following posters highlighting the use of the Thermogard XP in challenging cardiac surgery cases:

-- Use of a Novel Percutaneous Warming Catheter as a Protection Against Perioperative Hypothermia

-- Perioperative Therapeutic Hypothermia for Intraoperative Cardiac Arrest During Cardiac Surgery

-- Use of a Warming Catheter To Treat Perioperative Hypothermia in a Patient Undergoing Salvage Off-Pump RVAD Insertion

-- Reversal of Stroke by the Early Institution of Therapeutic Hypothermia after Cardiac Surgery

"Patients undergoing cardiac surgery are at risk for developing a variety of perioperative complications, including hypothermia and stroke," commented Dr. Blitz, senior author of the case studies to be featured at ASA. "Precise control of body temperature plays an important role in treating patients who are at risk for these complications.

"Patients who experience inadvertent hypothermia during surgery are at increased risk for bleeding and other adverse events, and therefore may benefit by being kept warm during the course of the operation," continued Dr. Blitz. "On the other hand, patients who experience a stroke or other neurological injury during surgery might actually benefit by being cooled down for a period of time after the surgery. Therefore, modulating temperature becomes a very important tool in the physician's armamentarium. The cases being presented at the ASA underscore the utility of temperature management for these situations."

Various factors contribute to hypothermia during surgery, including the type of surgical procedure, the type of anesthesia, the temperature of the operating room and the infusion of blood or other cold fluids. A patient's temperature can drop as much as 1 - 3 degrees F during the first 30 minutes after anesthesia is administered, and sometimes more body heat can be lost during the surgery, which can lead to serious complications including wound infections, blood loss, cardiac arrhythmias and heart damage.

Most methods of patient re-warming are imprecise, fail to warm the patient quickly enough or are not practical due to the type of surgery. The Alsius IVTM system is ideal for these circumstances since it does not interfere with the operating field and will precisely and efficiently regulate the patient's temperature.

Alsius IVTM(TM)

Alsius IVTM technology provides cooling and warming therapy via a computer-controlled temperature regulation system that connects to Alsius' proprietary heat exchange catheters. The catheters are inserted into a patient's subclavian, jugular or femoral vein, and circulate cool or warm saline through balloons that surround the catheter. This approach decreases or increases core temperature from the inside of the body out toward the exterior, allowing for significantly more rapid control of a patient's core body temperature, with greater efficiency and precision, compared to conventional external temperature management products such as cooling and warming blankets and ice packs.

Alsius' IVTM products include the CoolGard 3000(R), Thermogard(TM) and Thermogard XP(TM) systems, as well as a family of single-use catheters, including the Cool Line(R), Icy(TM), Quattro(TM), Solex(TM) and Fortius(R) catheters.

About Alsius

Alsius, headquartered in Irvine, CA, is a commercial-stage medical device company that develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is becoming the standard of care for patients in select critical conditions and those undergoing a variety of surgical procedures. Alsius markets a comprehensive suite of catheter-based intravascular temperature management products that address the need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. For more information, visit

Safe Harbor

This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking. Such forward looking statements, based upon the current beliefs and expectations of Alsius' management, are subject to risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The information set forth herein should be read in light of such risks. Additional information concerning such risks and uncertainties are contained in Alsius' filings with the Securities and Exchange Commission, which can be accessed electronically on the Securities and Exchange Commission website at

SOURCE Alsius Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
2. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
3. New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
4. New Studies Confirm Safety, Effectiveness of Balloon Sinuplasty(TM) Technology for Chronic Sinusitis
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Most Cancer Treatment Studies Arent Published, Study Finds
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
10. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
11. Genmab Announces Upcoming Ofatumumab Studies
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... 25, 2015 Research and Markets ( ... Market - Global Forecast to 2020" report to ... accounting for 37.21% of the total market share in ... region is projected to growth at the highest ... attributed primarily to the fast growing water, industrial gas ...
(Date:11/25/2015)... --> --> ... für das Patent über eine neue Hepatitis-B-Behandlung, welches sie ... an Enyo Pharma vergeben haben. Im Rahmen ... und von Edelris gemeinsam mit seinen Partnern Inserm und ... HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... Tuberous Sclerosis Complex (TSC), as well as raising public awareness of the disorder ... need it—presented a third donation of $35,000 to bolster progress at the Tuberous ...
(Date:11/25/2015)... ... ... Since its launch in 2012, the Regenestem brand ( ... to patients with chronic degenerative medical conditions. Now, the U.S. Patent and Trademark ... Organizations are required to hold a registered trademark in order to make licensing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to ... of the Create Real Impact awards. California Casualty is proud to support ... tide of distracted and reckless driving, the number one killer of young drivers. ...
Breaking Medicine News(10 mins):